Daewoong Pharmaceutical Shares Key Data from Phase 2 IPF Drug Trial at ERS 2026 #South_Korea #Seoul #IPF #Daewoong #Bersiporocin

Daewoong Pharmaceutical Shares Key Data from Phase 2 IPF Drug Trial at ERS 2026 #South_Korea #Seoul #IPF #Daewoong #Bersiporocin
Daewoong Pharmaceutical Unveils Comprehensive Data on 104 IPF Patients at ERS 2026 Conference #South_Korea #Seoul #Daewoong #Bersiporocin #IPF_Drug
A newly allowed US patent covers the lipid delivery system behind Daewoong’s experimental mRNA platform for reprogramming aged cells.
Link as first comment.